April 6 (Reuters) - IDEAYA Biosciences Inc IDYA.O:
IDEAYA BIOSCIENCES ANNOUNCES FIRST-PATIENT-IN FOR PHASE 1 TRIAL OF IDE574, A POTENTIAL FIRST-IN CLASS DUAL INHIBITOR OF KAT6/7 TO TARGET MULTIPLE SOLID TUMOR INDICATIONS, INCLUDING BREAST, PROSTATE, CRC, AND LUNG CANCER